The acquisition of Switzerland's PolyPeptide Group by Samsung Biologics (KRX:207940) is scheduled for settlement on Nov. 30, under a cash tender offer valued at 2.706 trillion won.
The board-approved plan targets 33 million shares, representing a 100% stake, according to parent Samsung C&T's (KRX:028260) bourse filing on Tuesday.
The target's largest shareholder, Draupnir Holding, has already committed to tendering its 55.65% stake, though the offer hinges on a minimum tender condition of roughly two-thirds of the fully diluted share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments